JAMA & ARCHIVES
Arch Fam Med
SEARCH
GO TO ADVANCED SEARCH
HOME  PAST ISSUES  TOPIC COLLECTIONS  CME  PHYSICIAN JOBS  CONTACT US  HELP
Institution: CLOCKSS  | My Account | E-mail Alerts | Access Rights | Sign In
  Vol. 8 No. 4, July 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (37)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Psychiatry
 •Depression
 •Randomized Controlled Trial
 •Alert me on articles by topic

Long-term Outcomes of Initial Antidepressant Drug Choice in a "Real World" Randomized Trial

Gregory E. Simon, MD, MPH; John Heiligenstein, MD; Dennis Revicki, PhD; Michael VonKorff, ScD; Wayne J. Katon, MD; Evette Ludman, PhD; Louis Grothaus, MA; Edward Wagner, MD, MPH

Arch Fam Med. 1999;8:319-325.

Objective  To compare the long-term clinical, quality-of-life, and economic outcomes after an initial prescription for fluoxetine, imipramine hydrochloride, or desipramine hydrochloride.

Design  Randomized, controlled trial.

Setting  Primary care clinics of a staff-model health maintenance organization in the Seattle, Wash, area.

Patients  Four hundred seventy-one adults beginning antidepressant drug treatment for depression.

Intervention  Random assignment of initial medication (desipramine, fluoxetine, or imipramine), with treatment (dosing, medication changes or discontinuation, and follow-up visits) managed by a primary care physician.

Measurements  Interviews at baseline and at 6, 9, 12, 18, and 24 months examined medication use, clinical outcomes (Hamilton Depression Rating Scale and depression subscale of the Hopkins Symptom Checklist), and quality of life (Medical Outcomes Study SF-36 Health Survey). Medical costs were assessed using the health maintenance organization's accounting data.

Results  Patients assigned to fluoxetine therapy were significantly more likely to continue taking the initial antidepressant but no more likely to continue any antidepressant therapy. The fluoxetine group did not differ significantly from either tricyclic drug group on any measure of depression severity or quality of life. For 24 months, antidepressant drug costs were approximately $250 higher for patients assigned to fluoxetine therapy, but total medical costs were essentially identical.

Conclusions  Initial selection of fluoxetine or a tricyclic antidepressant drug should lead to similar clinical outcomes, functional outcomes, and overall costs. Differences in antidepressant prescription costs are blunted by the large minority of tricyclic-treated patients who switch to use of more expensive medications. Restrictions on first-line use of fluoxetine in primary care will probably not reduce overall treatment costs.


From the Center for Health Studies, Group Health Cooperative (Drs Simon, VonKorff, Ludman, and Wagner and Mr Grothaus), and the Department of Psychiatry and Behavioral Sciences, University of Washington (Drs Simon and Katon), Seattle, Wash; Lilly Research Laboratories, Indianapolis, Ind (Dr Heiligenstein); and MEDTAP International, Bethesda, Md (Dr Revicki).


RELATED ARTICLES

The Archives of Family Medicine Continuing Medical Education Program
Arch Fam Med. 1999;8(4):291-293.
FULL TEXT  

TCAs vs SSRIs: Same Bang for Whose Buck?
Joseph J. Gallo
Arch Fam Med. 1999;8(4):326-327.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antidepressant Switching Among Adherent Patients Treated for Depression
Marcus et al.
Psychiatr. Serv. 2009;60:617-623.
ABSTRACT | FULL TEXT  

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
Anderson et al.
J Psychopharmacol 2008;22:343-396.
ABSTRACT  

Implications of part d for mentally ill dual eligibles: a challenge for medicare.
Morden and Garrison
Health Aff (Millwood) 2006;25:491-500.
ABSTRACT | FULL TEXT  

Continuity of Antidepressant Treatment for Adults With Depression in the United States
Olfson et al.
Am. J. Psychiatry 2006;163:101-108.
ABSTRACT | FULL TEXT  

Cost-effectiveness of Evidence-Based Pharmacotherapy or Cognitive Behavior Therapy Compared With Community Referral for Major Depression in Predominantly Low-Income Minority Women
Revicki et al.
Arch Gen Psychiatry 2005;62:868-875.
ABSTRACT | FULL TEXT  

Change in Psychosocial Functioning and Quality of Life of Patients With Body Dysmorphic Disorder Treated With Fluoxetine: A Placebo-Controlled Study
Phillips and Rasmussen
Psychosomatics 2004;45:438-444.
ABSTRACT | FULL TEXT  

Quantitative analysis of sponsorship bias in economic studies of antidepressants
Baker et al.
Br. J. Psychiatry 2003;183:498-506.
ABSTRACT | FULL TEXT  

Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients.
Charlier et al.
J Psychopharmacol 2002;16:369-372.
ABSTRACT  

Two-Year Effects of Quality Improvement Programs on Medication Management for Depression
Unutzer et al.
Arch Gen Psychiatry 2001;58:935-942.
ABSTRACT | FULL TEXT  

Antidepressant selection and economic outcome: a review of methods and studies from clinical practice
CROWN
Br. J. Psychiatry 2001;179 :s18-s22.
ABSTRACT | FULL TEXT  

Amitriptyline: still efficacious, but at what cost?
THOMPSON
Br. J. Psychiatry 2001;178:99-100.
FULL TEXT  

The Electronic Medical Record: A Randomized Trial of Its Impact on Primary Care Physicians' Initial Management of Major Depression
Rollman et al.
Arch Intern Med 2001;161:189-197.
ABSTRACT | FULL TEXT  

Managing Depression in Medical Outpatients
Whooley and Simon
NEJM 2000;343:1942-1950.
FULL TEXT  

More people with depression continued treatment with fluoxetine than with desipramine or imipramine
Anderson
Evid. Based Med. 2000;5:51-51.
FULL TEXT  

More people with depression continued treatment with fluoxetine than with desipramine or imipramine
Anderson
Evid. Based Ment. Health 2000;3:23-23.
FULL TEXT  

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines
Anderson et al.
J Psychopharmacol 2000;14:3-20.
ABSTRACT  

TCAs vs SSRIs: Same Bang for Whose Buck?
Gallo
Arch Fam Med 1999;8:326-327.
FULL TEXT  




HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.